Lysophosphatidic acid and ischemic heart disease
- VernacularTitle:溶血磷脂酸与缺血性心脏病
- Author:
Chunying XIU
;
Hui CAI
- Publication Type:Journal Article
- Keywords:
Lysophosphatidic acid;
Ischemic heart disease;
Atherosclerosis;
Myocardial infarction;
Myocardial hypertrophy
- From:
Journal of Medical Postgraduates
2004;0(02):-
- CountryChina
- Language:Chinese
-
Abstract:
Lysophosphatidic acid(LPA) is a potent bioactive lipid that has multiple specific effects on vessel wall cells,blood cells,cardiac myocytes and cardiac fibroblasts.Activated platelets are the primary source of LPA in circulation,which in turn stimulate platelet aggregation.It has shown that LPA can promote the formation of atherosclerosis and thrombus under certain conditions that might aggravate cardiovascular diseases,especially ischemic heart disease.LPA can enhance endothelial permeability and cause barrier dysfunction in the early phase of coronary atherosclerosis,as well as in the late phase trigger platlet activation and lead to intra-arterial thrombus formation upon rupture of the atherosclerotic plaque,finally cause myocardial ischemia and infarction.Furthermore,LPA can stimulate cardiac myocyte hypertrophy and fibroblasts proliferation,which aggravate myocardial hypertrophy after infarction.So,LPA plays an important role in the development of ischemic heart disease.
